Last reviewed · How we verify
0.1% bromfenac
At a glance
| Generic name | 0.1% bromfenac |
|---|---|
| Also known as | 0.5%Tobramycin dexamethasone, 0.3% sodium hyaluronate |
| Sponsor | Zhongshan Ophthalmic Center, Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Comparison of Treatments in Diabetic Macular Edema (PHASE4)
- PCME Prevention in Patients With NPDR (PHASE4)
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |